Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results

Eur Neurol. 1989;29(1):10-4. doi: 10.1159/000116368.

Abstract

30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study. Clinical parameters were assessed; cerebrospinal fluid and neurophysiological parameters (visual- and brainstem-evoked potentials) were evaluated at the beginning and at the end of treatment. Dexamethasone was more effective than ACTH and 6-methylprednisolone in shortening bout duration. Neither CSF nor neurophysiological parameters were significantly affected by therapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adrenocorticotropic Hormone / therapeutic use*
  • Adult
  • Dexamethasone / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Evoked Potentials, Auditory
  • Evoked Potentials, Visual
  • Humans
  • Methylprednisolone / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology
  • Random Allocation

Substances

  • Dexamethasone
  • Adrenocorticotropic Hormone
  • Methylprednisolone